Prenatal developmental toxicity evaluation of 2′,3′- dideoxyinosine (ddI) and 2′,3′-didehydro-3′-deoxythymidine (d4T) co-administered to Swiss albino (CD-1) mice

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 77, Issue 3, 2006, Pages 207-215

  Price, Catherine J ^a   George, Julia D ^a   Marr, Melissa C ^a   Myers, Christina B ^a   Bieler, Gayle S ^a   Williams, Rick L ^a   Jahnke, Gloria D ^b  

^a RTI INTERNATIONAL   (United States)

^b Sciences International Inc   (United States)

Author keywords

2 ,3 didehydro 3 deoxythymidine; 2 ,3 dideoxyinosine; AIDS drug combinations; d4T; ddI; Fetus; Mouse; Pregnancy

Indexed keywords

DIDANOSINE; STAVUDINE;

ADOLESCENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DEVELOPMENTAL TOXICITY; FEMALE; FETAL WELL BEING; FETUS; FETUS GENDER; FETUS MALFORMATION; FETUS WEIGHT; FOOD INTAKE; GENDER; GRAVID UTERUS WEIGHT; IMPLANTATION; LIVER WEIGHT; MATERNAL WEIGHT; MOUSE; MOUSE STRAIN; NONHUMAN; PREGNANCY; PRENATAL DEVELOPMENT; PRENATAL MORTALITY; PRIORITY JOURNAL; SWISS ALBINO MOUSE; SYMPTOMATOLOGY; UTERUS WEIGHT;

ANIMALS; ANIMALS, OUTBRED STRAINS; DIDANOSINE; EMBRYO IMPLANTATION; FEEDING BEHAVIOR; FEMALE; FETAL DEATH; FETAL WEIGHT; FETUS; LITTER SIZE; MICE; ORGAN SIZE; PREGNANCY; STAVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33745471313     PISSN: 15429733     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdrb.20076     Document Type: Article

References (55)

1. Bawdon RE, Sobhi S, Dax J. 1992. The transfer of anti-human immunodeficiency virus nucleoside compounds by the term human placenta. Am J Obstet Gynecol 167:1570-1574.
2. Bawdon RE, Kaul S, Sobhi S. 1994. The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta. Gynecol Obstet Invest 38:1-4.
3. Bieler GS, Williams RL. 1995. Cluster sampling techniques in quantal response teratology and developmental toxicity studies. Biometrics 51:764-776.
4. Blair E. 1971. Hypothermia. Chapter 38. In: Soma L, editor. Textbook of veterinary anesthesia. Baltimore, MD: Williams and Wilkins. p 555-579.
5. Chappuy H, Treluyer JM, Jullien V, Dimet J, Rey E, Fouche M, Firtion G, Pons G, Mandelbrot L. 2004. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 48:4332-4336.
6. Dalton JT, Au JL. 1993. 2′,3′-Dideoxyinosine is not metabolized in human placenta. Drug Metab Dispos 21:544-546.
7. Dancis J, Lee JD, Mendoza S, Liebes L. 1993. Transfer and metabolism of dideoxyinosine by the perfused human placenta. J Acquir Immune Defic Syndr 6:2-6.
8. Dancis J, Liebes L. 1995. Drug delivery during pregnancy: evaluation in vitro of new drugs. Reprod Fertil Dev 7:1485-1489.
9. Danneman PJ, Mandrell TD. 1997. Evaluation of five agents/methods for anesthesia of neonatal rodents. Lab Anim Sci 47:386-395.
10. De Clercq E. 2005. Emerging anti-HIV drugs. Expert Opin Emerg Drugs 10:241-273.
11. Gaou I, Malliti M, Guimont M-C, Lettéron P, Demeilliers C, Peytavin G, Degott C, Pessayre D, Fromenty B. 2001. Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice. J Pharmacol Exp Ther 297:516-523.
12. Grizzle TB, Collins BJ, Rao GN, Hill JM, Gaudette NF, Handy RW. 1994. Effect of stomach pH on absolute bioavailability (F) of 2′,3′- dideoxyinosine (ddI) in female CD-1® Swiss mice. Toxicologist 14:115.
13. Hafez ESE. 1970. Reproduction and breeding techniques for laboratory animals. Philadelphia: Lea and Febiger.
14. Henderson GI, Perez AB, Yang Y, Hamby RL, Schenken RS, Schenker S. 1994. Transfer of dideoxyinosine across the human isolated placenta. J Clin Pharmacol 38:237-242.
15. Kaul S, Dandekar KA, Schilling BE, Barbhaiya RH. 1999. Review: toxicokinetics of 2′,3′-didehydro-3′-deoxythymidine, stavudine (d4T). Drug Metab Dispos 27:1-12.
16. Lea AP, Faulds D. 1996. Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs 51:846-864.
17. Lumb WV, Jones EW. 1973. Anesthesia in laboratory and zoo animals. In: Veterinary anesthesia. Chapter 18. Philadelphia: Lea and Febiger. p 452-453.
18. Marr MC, Myers CB, George JD, Price CJ. 1988. Comparison of single and double staining for evaluation of skeletal development: the effects of ethylene glycol (EG) in CD rats. Teratology 37:476.
19. Minkoff H, Augenbraun M. 1997. Antiretroviral therapy for pregnant women. Am J Obstet Gynecol 176:478-489.
20. Mirochnick M, Capparelli E. 2004. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 43:1071-1087.
21. Mobley JE, Pollard RB, Schrader S, Adler MH, Kelleher T, McLaren C, the AI454-143 Team. 1999. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AIDS 13:F87-F93.
22. Narotsky MG, Schmid JE, Andrews JE, Kavlock RJ. 1998. Effects of boric acid on axial skeletal development in rats. Biol Trace Elem Res 66:373-394.
23. Nelson BR. 1994. Interactions in developmental toxicology: a literature review and terminology proposal. Teratology 49:33-71.
24. National Toxicology Program. 1992. Reproductive/developmental/general toxicity study of 2′,3′-dideoxyinosine (ddI) in CD-1 mice. SRI-Chm-92-923-7500-XX; SRI Study A35-TXM-1. NIEHS Contract No. N01-ES-15328. NIEHS/National Toxicology Program Chem-Track No. RACB92126. Report Date: November 23, 1992.
25. National Toxicology Program. 1993. The bioavailability and dose proportionality of 2′,3′-dideoxyinosine when administered in non-buffered and buffered vehicles to Swiss (CD-1®) female mice. 2′,3′-dideoxyinosine J07. NIEHS Task No. 50306. NIEHS Contract No. N01-ES-15307, Report Date: September 30, 1993.
26. National Toxicology Program. 2000. National Toxicology Program Study Database. Immunotoxicity studies of 2′,3′-dideoxyinosine (CAS No. 69655-05-6) in female C57BL/6 mice (National Toxicology Program Report No. IMM94006). http://ntp-server.niehs.nih.gov/htdocs/IT-studies/IMM94006.html, Report Date: February 1996. Accessed November 20, 2000, February 19, 2002.
27. National Toxicology Program. 2002a. Final Letter Report. Developmental toxicity screen of 2′3′-dideoxyinosine (ddI; CAS No. 69655-05-6) and 2′3′-didehydro-3′-deoxythymidine (d4T; CAS No. 3056-17-5) co-administered by gavage to Swiss albino (CD-1®) mice on gestational days 6 through 16 (RTI Study Code Mi02-PDXD; TRP-20-101). NIEHS/National Toxicology Program Contract N01-ES-65405. Report Date: July 29, 2002.
28. National Toxicology Program. 2002b. Developmental toxicity evaluation of 3′-azido-3′-deoxythymidine (AZT; CAS No. 30516-87-1) and 2′,3′-dideoxycytidine (ddC; CAS No. 7481-89-2) administered by gavage to Swiss albino (CD-1®) mice on gestational days 6 through 15. RTI Study Code Mi97-XDDC, RTI, Research Triangle Park, NC. NIEHS/National Toxicology Program Contract N01-ES-65405; National Toxicology Program Study No. TER-97-001. Final Report Date: February 14, 2002.
29. National Toxicology Program. 2004. Developmental toxicity evaluation of 2′3′-dideoxyinosine (ddI; CAS No. 69655-05-6) and 2′3′-didehydro-3′-deoxythymidine (d4T; CAS No. 3056-17-5) co-administered by gavage to Swiss albino (CD-1®) mice on gestational days 6 through 16 (RTI Study Code Mi02-DDXD; TER-20-201). NIEHS/National Toxicology Program Contract N01-ES-65405. Report Date: March 26, 2004.
30. Patterson TA, Schmued LC, Sandberg JA, Slikker W Jr. 2000. Temporal development of 2′,3′-dideoxyinosine (ddI)-induced peripheral myelinopathy. Neurotoxicol Teratol 22:429-434.
31. Physician's Desk Reference. 1999a. Videx (didanosine). In: Physician's desk reference, 53rd edition. Montvale, NJ: Medical Economics Company, Inc. p 806-810.
32. Physician's Desk Reference. 1999b. Zerit (stavudine). In: Physician's desk reference, 53rd edition. Montvale, NJ: Medical Economics Company, Inc. p 812-815.
33. Phillips KE, McCay JA, Brown RD, Musgrove DL, Meade BJ, Butterworth LF, Wilson S, White KL Jr, Munson AE. 1997. Immunotoxicity of 2′,3′- dideoxyinosine in female B6C3F1 mice. Drug Chem Toxicol 20:189-228.
34. Phillips KE, Munson AE. 1997. 2′3′-Dideoxyinosine inhibits the humoral immune response in female B6C3F1 mice by targeting the B lymphocyte. Toxicol Appl Pharmacol 145:260-267.
35. Price CJ, Marr MC, Myers CB, Bieler GS, Williams RL, Rao G, Jahnke GD. 2002. Developmental toxicity of 3′-azido-3′-deoxythymidine (AZT) and 2′,3′-dideoxycytidine (ddC) co-administered to CD-1® mice on gestational days (GD) 6 through 15. Teratology 65:340.
36. Price CJ, Marr MC, Myers CB, Bieler GS, Williams RL, Jahnke GD. 2004. Developmental toxicity evaluation of 3′-azido-3′-deoxythymidine (AZT) and (-) 2′,3′-dideoxy-3′-thiacytidine (3TC) co-administered by gavage to Swiss albino (CD-1®) mice on gestational days (GD) 6 through 16. Birth Defects Res A Clin Mol Teratol 70:316.
37. Raffi F, Reliquet V, Auger S, Besnier J-M, Chennebault J-M, Billaud E, Michelet C, Perre P, Lafeuillade A, May T, Billaudel S. 1998. Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral- experienced patients. AIDS 12:1999-2005.
38. Russell JW, Whiterock VJ, Marrero D, Klunk LJ. 1990. Disposition in animals of a new anti-HIV agent: 2′,3′-didehydro-3′- deoxythymidine. Drug Metab Dispos 18:153-157.
39. Salewski E. 1964. Färbemethode zum makroskopischen Nachweis von Implantationsstellen am Uterus der Ratte. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 247:367.
40. Sarner L, Fakoya A. 2002. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect 78:58-59
41. (Erratum: Sex Transm Infect 79:429).
42. Schiffman SS, Zervakis J, Shaio E, Heald AE. 1999. Effect of the nucleoside analogs zidovudine, didanosine, stavudine, and lamivudine on the sense of taste. Nutrition 15:854-859.
43. Schilling BE, Nelson BR, Proctor JE, Diamond SS, Kaul S, Hawkins HC. 1995. The nonclinical toxicologic profile of stavudine. Curr Ther Res 56:201-218.
44. Schmued LC, Albertson CM, Andrews A, Sandberg JA, Nickols J, Slikker W Jr. 1996. Evaluation of brain and nerve pathology in rats chronically dosed with ddI or isoniazid. Neurotoxicol Teratol 18:555-563.
45. Sieh E, Coluzzi ML, Cusella de Angelis MG, Mezzogiorno A, Floridia M, Canipari R, Cossu G, Vella S. 1992. The effects of AZT and ddI on pre- and postimplantation mammalian embryos: an in vivo and in vitro study. AIDS Res Hum Retroviruses 8:639-649.
46. Staples RE. 1974. Detection of visceral alterations in mammalian fetuses. Teratology 9:7.
47. Stuckhardt JL, Poppe SM. 1984. Fresh visceral examination of rat and rabbit fetuses used in teratogenicity testing. Teratogen Carcinogen Mutagen 4:181-188.
48. United States Food and Drug Administration. 1988. Good laboratory practice regulations for nonclinical laboratory studies. Code of federal regulations (CFR) (April 1). p 229-243. Washington, D.C.: U.S. Government Printing Office.
49. United States Food and Drug Administration. 1994. Good laboratory practice regulations for nonclinical laboratory studies. Code of federal regulations (CFR) (March 21) 56FR12300. Washington, D.C.: U.S. Government Printing Office.
50. United States Food and Drug Administration. 2001. FDA Consumer magazine (May-June 2001). Warning for pregnant women on HIV therapy. Available at: http://www.fda.gov/fdac/departs/2001/301_upd.html. Accessed May 2, 2006.
51. United States Public Health Service. 2005. Public Health Service Task Force. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States (February 24, 2005) and supplement: safety and toxicity of individual antiretroviral agents in pregnancy (February 24, 2005). http://www.aidsinfo.nih.gov. Accessed June 14, 2005.
52. van der Aa EM, Peereboom-Stegeman JHJC, Noordhoek J, Gribnau FWJ, Russel FGM. 1998. Mechanisms of drug transfer across the human placenta. Pharm World Sci 20:139-148.
53. Warner WA, Bregman CL, Comereski CR, Arezzo JC, Davidson TJ, Knupp CA, Kauls S, Durham SK, Wasserman AJ, Frantz JD. 1995. Didanosine (ddI) and stavudine (d4T): absence of peripheral neurotoxicity in rabbits. Food Chem Toxicol 33:1047-1050.
54. Wilson JG. 1965. Embryological considerations in teratology. In: Wilson JG, Warkany J, editors. Teratology: principals and techniques. Chicago: University of Chicago Press, p 251-277.
55. Wixson SK, Smiler KL. 1997. Anesthesia and analgesia in rodents. Chapter 9. In: Kohn DF, Wixson SK, White WJ, Benson GJ, editors. Anesthesia and analgesia in laboratory animals. New York: American College of Laboratory Animal Medicine Series, p 165-203.